Departments of Medicine.
Medicine, Division of Gastroenterology and Hepatology, and Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles.
J Clin Gastroenterol. 2018 Nov/Dec;52(10):913-917. doi: 10.1097/MCG.0000000000000984.
To evaluate the predictive value of hypoalbuminemia on liver transplant (LT) waitlist survival and probability of receiving LT among adults with end-stage liver disease (ESLD).
Growing evidence reports on the negative prognostic value of hypoalbuminemia among ESLD patients awaiting LT.
Using 2003 to 2015 United Network for Organ Sharing data, we retrospectively evaluated the impact of mild-moderate (2.5 to 3.4 g/dL) and severe hypoalbuminemia (<2.5 g/dL) on waitlist survival and probability of receiving LT among US adults awaiting LT. Outcomes were stratified by liver disease etiology and presence of hepatocellular carcinoma (HCC), and evaluated using Kaplan-Meier and multivariate Cox proportional hazards models.
Among 128,450 adults listed for LT, 27.1% had normal albumin (≥3.5 g/dL), 53.7% mild-moderate hypoalbuminemia (2.5 to 3.4 g/dL), and 19.2% severe hypoalbuminemia (<2.5 g/dL) at time of listing. Patients with severe hypoalbuminemia had significantly lower 1-year waitlist survival compared with those with normal albumin (80.4% vs. 95.2%; P<0.001). On multivariate regression, severity of hypoalbuminemia was associated with increasing waitlist mortality, even after correcting for model for end stage liver disease-sodium and HCC [albumin, 2.5 to 3.4 g/dL: hazard ratio (HR), 1.81; 95% confidence interval (CI), 1.62-2.01; P<0.001; <2.5 g/dL: HR, 2.46; 95% CI, 2.20-2.76; P<0.001]. Patients with hypoalbuminemia had significantly lower probability of receiving LT compared with those with normal albumin (albumin <2.5 g/dL: HR, 0.80; 95% CI, 0.78-0.83; P<0.001).
ESLD patients with hypoalbuminemia have lower probability of LT despite significantly higher waitlist mortality compared with patients with normal albumin. If validated by further studies, incorporation of albumin into prognostication systems may improve the performance of US donor organ allocation systems.
评估低蛋白血症对肝移植(LT)等待名单上的生存和终末期肝病(ESLD)成人接受 LT 概率的预测价值。
越来越多的证据表明,低蛋白血症在等待 LT 的 ESLD 患者中具有负预后价值。
使用 2003 年至 2015 年美国器官共享网络的数据,我们回顾性评估了轻度至中度(2.5 至 3.4g/dL)和重度低蛋白血症(<2.5g/dL)对美国 LT 等待名单上的成年人的等待名单生存和接受 LT 概率的影响。根据肝脏疾病病因和肝细胞癌(HCC)的存在对结果进行分层,并使用 Kaplan-Meier 和多变量 Cox 比例风险模型进行评估。
在 128450 名接受 LT 的成年人中,27.1%的白蛋白正常(≥3.5g/dL),53.7%的白蛋白轻度至中度降低(2.5 至 3.4g/dL),19.2%的白蛋白严重降低(<2.5g/dL)。与白蛋白正常的患者相比,严重低蛋白血症患者的 1 年等待名单生存率显著降低(80.4% vs. 95.2%;P<0.001)。在多变量回归中,即使在纠正终末期肝病钠模型和 HCC 后,低蛋白血症的严重程度与等待名单死亡率的增加相关[白蛋白 2.5 至 3.4g/dL:风险比(HR)1.81;95%置信区间(CI)1.62-2.01;P<0.001;<2.5g/dL:HR 2.46;95%CI 2.20-2.76;P<0.001]。与白蛋白正常的患者相比,低蛋白血症患者接受 LT 的概率显著降低(白蛋白<2.5g/dL:HR 0.80;95%CI 0.78-0.83;P<0.001)。
尽管与白蛋白正常的患者相比,低蛋白血症的 ESLD 患者等待名单死亡率显著更高,但他们接受 LT 的概率却较低。如果进一步的研究验证了这一结果,将白蛋白纳入预后系统可能会提高美国供体器官分配系统的性能。